Relacje inwestorskie > Investors

Genomed Joint-Stock Co. debuted on the NewConnect Market on May 30, 2011.

The company provides services in the field of DNA sequencing, analysis and synthesis to over 200 research and medical institutions, and biotechnological firms. Genomed’s activities are directed towards implementing modern technology within the domain of personalized medicine on the basis of DNA sequencing and the diagnostics of genetic disorders. The company raised almost 3 mln PLN in a private offering, which it invested in development and further expansion.


Aktualnosci Inwestorzy

| In the Polish market, Genomed is the only company whose staff and technological base make possible processing orders involving Next Generation Sequencing (NGS), including human genome analysis, and the subsequent reading. With respect to its innovative character, the service, a permanent addition to [ ... ] więcej »
aktualizacja: 15-05-2013 09:46:31


odwiedź nas na facebooku
© Copyright by Genomed S.A. Wykonanie: Delta Interactive